Hospira Recalls Labetalol Injection Due to Particulate Matter
Hospira Inc. recalls specific lots of Labetalol Hydrochloride Injection due to metal particles in the glass vial and floating debris.
Recall notice
Presence of Particulate Matter; metal embedded in the glass vial and visible particles floating in the solution
Contact the company
What happened, in plain English
Hospira Inc. is recalling a specific lot of Labetalol Hydrochloride Injection, USP because it contains particulate matter, including metal embedded in the glass vial and visible particles floating in the solution. The recall affects 45,448 vials distributed nationwide. The record does not specify a remedy or action for consumers. Read more at govinfonow.com/recall/46038-hospira-inc-recalls-labetalol-hydrochloride-injection-usp-100-mg-20.
Source Summary by GovInfoNow · govinfonow.com/recall/46038-hospira-inc-recalls-labetalol-hydrochloride-injection-usp-100-mg-20 · Updated October 12, 2026 · FDA enforcement record: FDA #D-1424-2014
Cite this page
“Hospira Recalls Labetalol Injection Due to Particulate Matter.” GovInfoNow, updated October 12, 2026. https://govinfonow.com/recall/46038-hospira-inc-recalls-labetalol-hydrochloride-injection-usp-100-mg-20. Based on FDA recall #D-1424-2014 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1424-2014%22&limit=1).
Why it’s dangerous
The presence of metal embedded in the glass vial and visible particles floating in the solution poses a contamination risk. Ingesting or injecting particulate matter can lead to serious health complications, although the specific injury mechanism is not detailed in the record.
Who’s affected
Patients who have been prescribed or received Labetalol Hydrochloride Injection from the affected lot are at risk of exposure to foreign particles. Healthcare providers administering this medication may also be impacted.
How to tell if you have this one
Check if you have Labetalol Hydrochloride Injection, USP, 100 mg/20 mL (5 mg/mL), 20 mL Multidose Vial. Look for NDC 0409-2267-20 and Lot number 36225DD with an expiration date of 12/01/2015.
- Brand
Hospira- Category
Drug
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 2.8 years after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1424-2014 (May 16, 2014) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1424-2014 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 12, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.